Vascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasis

References

• ChristophersEPsoriasis – epidemiology and clinical spectrumClin Exp Dermatol200126431432011422182
   PubMed Web of Science ®Google Scholar
• RappSRFeldmanSRExumMLFleischerABReboussinDMPsoriasis causes as much disability as other major medical diseasesJ Am Acad Dermatol1999413 Pt 140140710459113
   PubMed Web of Science ®Google Scholar
• ArmstrongAWHarskampCTArmstrongEJPsoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studiesJ Am Acad Dermatol201368465466223360868
   PubMed Web of Science ®Google Scholar
• GriffithsCEBarkerJNPathogenesis and clinical features of psoriasisLancet2007370958326327117658397
   PubMed Web of Science ®Google Scholar
• BarkerJNThe pathophysiology of psoriasisLancet199133887612272301676787
   PubMed Web of Science ®Google Scholar
• LowesMABowcockAMKruegerJGPathogenesis and therapy of psoriasisNature2007445713086687317314973
   PubMed Web of Science ®Google Scholar
• CoimbraSFigueiredoACastroERocha-PereiraPSantos-SilvaAThe roles of cells and cytokines in the pathogenesis of psoriasisInt J Dermatol2012514389395 quiz 39522435425
   PubMed Web of Science ®Google Scholar
• DetmarMBrownLFClaffeyK POverexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasisJ Exp Med19941803114111468064230
   PubMed Web of Science ®Google Scholar
• YoungHSSummersAMBhushanMBrenchleyPEGriffithsCESingle-nucleotide polymorphisms of vascular endothelial growth factor in psoriasis of early onsetJ Invest Dermatol2004122120921514962110
   PubMed Web of Science ®Google Scholar
• HernándezGLVolpertOVIñiguezMASelective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2J Exp Med2001193560762011238591
   PubMed Web of Science ®Google Scholar
• García-CaballeroMMarí-BeffaMMedinaMÁQuesadaARDimethylfumarate inhibits angiogenesis in vitro and in vivo: a possible role for its antipsoriatic effect?J Invest Dermatol201113161347135521289642
   PubMed Web of Science ®Google Scholar
• MeissnerMDollMHrgovicISuppression of VEGFR2 expression in human endothelial cells by dimethylfumarate treatment: evidence for anti-angiogenic actionJ Invest Dermatol201113161356136421430706
   PubMed Web of Science ®Google Scholar
• MarkhamTMullanRGolden-MasonLResolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapyJ Am Acad Dermatol20065461003101216713454
   PubMed Web of Science ®Google Scholar
• GoedkoopAYKraanMCPicavetDIDeactivation of endothe-lium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre studyArthritis Res Ther200464R326R33415225368
   PubMed Web of Science ®Google Scholar
• DengHYa nCLHuYXuYLiaoKHPhotochemotherapy inhibits angiogenesis and induces apoptosis of endothelial cells in vitroPhotodermatol Photoimmunol Photomed200420419119915238097
   PubMed Web of Science ®Google Scholar
• AkmanADicleOYilmazFCoskunMYilmazEDiscrepant levels of vascular endothelial growth factor in psoriasis patients treated with PUVA, Re-PUVA and narrow-band UVBPhotodermatol Photoimmunol Photomed200824312312718477130
   PubMed Web of Science ®Google Scholar
• KubotaYTumor angiogenesis and anti-angiogenic therapyKeio J Med2012612475622760023
   PubMedGoogle Scholar
• KerrDJTargeting angiogenesis in cancer: clinical development of bevacizumabNat Clin Pract Oncol200411394316264798
   PubMedGoogle Scholar
• ChangJHGargNKLundeEHanKYJainSAzarDTCorneal neovascularization: an anti-VEGF therapy reviewSurv Ophthalmol201257541542922898649
   PubMed Web of Science ®Google Scholar
• ChiangARegilloCDPreferred therapies for neovascular age-related macular degenerationCurr Opin Ophthalmol201122319920421427571
   PubMed Web of Science ®Google Scholar
• AkmanAYilmazEMutluHOzdoganMComplete remission of psoriasis following bevacizumab therapy for colon cancerClin Exp Dermatol2009345e202e20419077094
   PubMed Web of Science ®Google Scholar
• KeshtgarpourMDudekAZSU-011248, a vascular endothelial growth factor receptor-tyrosine kinase inhibitor, controls chronic psoriasisTransl Res2007149310310617320795
   PubMed Web of Science ®Google Scholar
• FournierCTismanGSorafenib-associated remission of psoriasis in hypernephroma: case reportDermatol Online J20101621720178713
   PubMedGoogle Scholar
• NarayananSCallis-DuffinKBattenJAgarwalNImprovement of psoriasis during sunitinib therapy for renal cell carcinomaAm J Med Sci2010339658058120421784
   PubMed Web of Science ®Google Scholar
• XiaY PLiBHyltonDDetmarMYancopoulosGDRudgeJSTransgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasisBlood2003102116116812649136
   PubMed Web of Science ®Google Scholar
• FolkmanJShingYAngiogenesisJ Biol Chem19922671610931109341375931
   PubMed Web of Science ®Google Scholar
• FolkmanJThe role of angiogenesis in tumor growthSemin Cancer Biol19923265711378311
   PubMedGoogle Scholar
• BianchiEScarinciFGrandeCImmunohistochemical profile of VEGF, TGF-β and PGE2 in human pterygium and normal conjunctiva: experimental study and review of the literatureInt J Immunopathol Pharmacol201225360761523058011
   PubMed Web of Science ®Google Scholar
• BrenchleyPEAngiogenesis in inflammatory joint disease: a target for therapeutic interventionClin Exp Immunol2000121342642910971506
   PubMed Web of Science ®Google Scholar
• FerraraNVascular endothelial growth factor: basic science and clinical progressEndocr Rev200425458161115294883
   PubMed Web of Science ®Google Scholar
• KiselyovABalakinK VTkachenkoSEVEGF/VEGFR signalling as a target for inhibiting angiogenesisExpert Opin Investig Drugs200716183107
   PubMed Web of Science ®Google Scholar
• ShinkarukSBayleMLaïnGDélérisGVascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapyCurr Med Chem Anticancer Agents2003329511712678905
   PubMedGoogle Scholar
• ClaussMGerlachMGerlachHVascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migrationJ Exp Med19901726153515452258694
   PubMed Web of Science ®Google Scholar
• FerraraNGerberH PLeCouterJThe biology of VEGF and its receptorsNat Med20039666967612778165
   PubMed Web of Science ®Google Scholar
• HouckKALeungDWRowlandAMWinerJFerraraNDual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanismsJ Biol Chem19922673626031260371464614
   PubMed Web of Science ®Google Scholar
• TakahashiSVascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapyBiol Pharm Bull201134121785178822130231
   PubMed Web of Science ®Google Scholar
• CarmelietPFerreiraVBreierGAbnormal blood vessel development and lethality in embryos lacking a single VEGF alleleNature199638065734354398602241
   PubMed Web of Science ®Google Scholar
• BroganIJKhanNIsaacKHutchinsonJAPravicaVHutchinsonIVNovel polymorphisms in the promoter and 5′ UTR regions of the human vascular endothelial growth factor geneHum Immunol199960121245124910626738
   PubMed Web of Science ®Google Scholar
• WatsonCJWebbNJBottomleyMJBrenchleyPEIdentification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein productionCytokine20001281232123510930302
   PubMed Web of Science ®Google Scholar
• YoungHSSummersAMReadIRInteraction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasisJ Invest Dermatol2006126245345916385345
   PubMed Web of Science ®Google Scholar
• BhushanMMcLaughlinBWeissJBGriffithsCELevels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasisBr J Dermatol199914161054106010606852
   PubMed Web of Science ®Google Scholar
• AndrysCBorskaLPohlDFialaZHamakovaKKrejsekJAngiogenic activity in patients with psoriasis is significantly decreased by Goeckerman’s therapyArch Dermatol Res20072981047948317221216
   PubMed Web of Science ®Google Scholar
• CreamerDAllenMJaggarRStevensRBicknellRBarkerJMediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factorArch Dermatol2002138679179612056961
   PubMedGoogle Scholar
• MatsumuraYAnanthaswamyHNShort-term and long-term cellular and molecular events following UV irradiation of skin: implications for molecular medicineExpert Rev Mol Med200242612214585163
   PubMedGoogle Scholar
• YanoKKadoyaKKajiyaKHongYKDetmarMUltraviolet B irradiation of human skin induces an angiogenic switch that is mediated by upregulation of vascular endothelial growth factor and by downregulation of thrombospondin-1Br J Dermatol2005152111512115656811
   PubMed Web of Science ®Google Scholar
• BielenbergDRBucanaCDSanchezRDonawhoCKKripkeMLFidlerIJMolecular regulation of UVB-induced cutaneous angiogenesisJ Invest Dermatol199811158648729804351
   PubMed Web of Science ®Google Scholar
• ArbiserJLFumarate esters as angiogenesis inhibitors: key to action in psoriasis?J Invest Dermatol201113161189119121566578
   PubMed Web of Science ®Google Scholar
• GiraudoEPrimoLAuderoETumor necrosis factor-alpha regulates expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cellsJ Biol Chem19982733422128221359705358
   PubMed Web of Science ®Google Scholar
• BrotasAMCunhaJMLagoEHMachadoCCCarneiroSCTumor necrosis factor-alpha and the cytokine network in psoriasisAn Bras Dermatol2012875673681 quiz 68223044557
   PubMed Web of Science ®Google Scholar
• TobinAMKirbyBTNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritisBioDrugs2005191475715691217
   PubMed Web of Science ®Google Scholar
• KorpantyGSmythEAnti-VEGF strategies – from antibodies to tyrosine kinase inhibitors: background and clinical development in human cancerCurr Pharm Des201218192680270122390756
   PubMed Web of Science ®Google Scholar
• VerittiDSaraoVLanzettaPNeovascular age-related macular degenerationOphthalmologica2012227Suppl 1112022517121
   PubMed Web of Science ®Google Scholar
• AggarwalCSomaiahNSimonGAntiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed? Cancer Biol Ther201213524726322481432
   PubMed Web of Science ®Google Scholar
• PrestaLGChenHO’ConnorSJHumanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disordersCancer Res19975720459345999377574
   PubMed Web of Science ®Google Scholar
• CohenMHGootenbergJKeeganPPazdurRFDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancerOncologist200712335636117405901
   PubMed Web of Science ®Google Scholar
• CohenMHGootenbergJKeeganPPazdurRFDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent non-squamous non-small cell lung cancerOncologist200712671371817602060
   PubMed Web of Science ®Google Scholar
• SummersJCohenMHKeeganPPazdurRFDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinomaOncologist201015110411120061402
   PubMed Web of Science ®Google Scholar
• AghajanianCBlankS VGoffBAOCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancerJ Clin Oncol201230172039204522529265
   PubMed Web of Science ®Google Scholar
• SaeedMUGkaragkaniEAliKEmerging roles for antiangio-genesis factors in management of ocular diseaseClin Ophthalmol2013653354323515639
   PubMedGoogle Scholar
• FerraraNDamicoLShamsNLowmanHKimRDevelopment of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degenerationRetina (Philadelphia, Pa)2006268859870
   PubMed Web of Science ®Google Scholar
• HolashJDavisSPapadopoulosNVEGF-Trap: a VEGF blocker with potent antitumor effectsProc Natl Acad Sci U S A20029917113931139812177445
   PubMed Web of Science ®Google Scholar
• StewartM WGripponSKirkpatrickPAflibercept in the treatment of metastatic colorectal cancerNat Rev Drug Discov201211426927022460118
   PubMed Web of Science ®Google Scholar
• WangTFLockhartACAflibercept in the treatment of metastatic colorectal cancerClin Med Insights Oncol20126193022253552
   PubMedGoogle Scholar
• TarhiniAAFrankelPMargolinKAAflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal originClin Cancer Res201117206574658121880788
   PubMed Web of Science ®Google Scholar
• TwardowskiPStadlerWMFrankelPPhase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium TrialUrology201076492392620646741
   PubMed Web of Science ®Google Scholar
• AminiAMasoumi MoghaddamSMorrisDLPourgholamiMHUtility of vascular endothelial growth factor inhibitors in the treatment of ovarian cancer: from concept to applicationJ Oncol2012201254079121961001
   PubMedGoogle Scholar
• de GrootJFLambornKRChangSMPhase II study of afiber-cept in recurrent malignant glioma: a North American Brain Tumor Consortium studyJ Clin Oncol201129192689269521606416
   PubMed Web of Science ®Google Scholar
• ApteRSPegaptanib sodium for the treatment of age-related macular degenerationExpert Opin Pharmacother20089349950818220500
   PubMed Web of Science ®Google Scholar
• ManningGWhyteDBMartinezRHunterTSudarsanamSThe protein kinase complement of the human genomeScience200229856001912193412471243
   PubMed Web of Science ®Google Scholar
• ImaiKTakaokaAComparing antibody and small-molecule therapies for cancerNat Rev Cancer20066971472716929325
   PubMed Web of Science ®Google Scholar
• MorabitoAPiccirilloMCFalasconiFVandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directionsOncologist200914437839019349511
   PubMed Web of Science ®Google Scholar
• RibattiDTyrosine kinase inhibitors as antiangiogenic drugs in multiple myelomaPharmaceuticals2010312251231
   Google Scholar
• O’SheaJJLaurenceAMcInnesIBBack to the future: oral targeted therapy for RA and other autoimmune diseasesNat Rev Rheumatol20139317318223419429
   PubMed Web of Science ®Google Scholar
• HalinCFahrngruberHMeingassnerJGInhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitorAm J Pathol2008173126527718535184
   PubMed Web of Science ®Google Scholar
• RockE PGoodmanVJiangJXFood and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinomaOncologist200712110711317227905
   PubMed Web of Science ®Google Scholar
• MendelDBLairdADXinXIn vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationshipClin Cancer Res20039132733712538485
   PubMed Web of Science ®Google Scholar
• RaymondEHammelPDreyerCSunitinib in pancreatic neuroendocrine tumorsTarget Oncol20127211712522661319
   PubMed Web of Science ®Google Scholar
• VelhoTRKapiteijnEJagerMJNew therapeutic agents in uveal melanomaAnticancer Res20123272591259822753717
   PubMed Web of Science ®Google Scholar
• EscudierBEisenTStadlerWMTARGET Study GroupSorafenib in advanced clear-cell renal-cell carcinomaN Engl J Med2007356212513417215530
   PubMed Web of Science ®Google Scholar
• LangLFDA approves sorafenib for patients with inoperable liver cancerGastroenterolog y20081342379
   Web of Science ®Google Scholar
• ZhangJGoldKAKimESorafenib in non-small cell lung cancerExpert Opin Investig Drugs201221914171426
   PubMed Web of Science ®Google Scholar
• ZauliGVoltanRTisatoVSecchieroPState of the art of the therapeutic perspective of sorafenib against hematological malignanciesCurr Med Chem201219284875488422934770
   PubMed Web of Science ®Google Scholar
• WilhelmSMAdnaneLNewellPVillanuevaALlovetJMLynchMPreclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signalingMol Cancer Ther20087103129314018852116
   PubMed Web of Science ®Google Scholar
• ZhuXWuSDahutWLParikhCRRisks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysisAm J Kidney Dis200749218619317261421
   PubMed Web of Science ®Google Scholar
• van HeeckerenWJSanbornSLNarayanAComplications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosisCurr Opin Hematol200714546848017934353
   PubMed Web of Science ®Google Scholar
• ZehetnerCKirchmairRHuberSKralingerMTKieselbachGFPlasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedemaBr J Ophthalmol201397445445923385630
   PubMed Web of Science ®Google Scholar
• WuLMartínez-CastellanosMAQuiroz-MercadoHPan American Collaborative Retina Group (PACORES)Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES)Graefes Arch Clin Exp Ophthalmol20082461818717674014
   PubMed Web of Science ®Google Scholar
• CurtisLHHammillBGSchulmanKACousinsS WRisks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degenerationArch Ophthalmol2010128101273127920937996
   PubMed Web of Science ®Google Scholar
• GilliesMCWongT YRanibizumab for neovascular age-related macular degenerationN Engl J Med200735677489 author reply 74917310523
   PubMed Web of Science ®Google Scholar
• SchmuckerCEhlkenCAgostiniHTA safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandardPLoS One201278e4270122880086
   PubMed Web of Science ®Google Scholar
• StewartMWThe expanding role of vascular endothelial growth factor inhibitors in ophthalmologyMayo Clin Proc2012871778822212972
   PubMed Web of Science ®Google Scholar
• HutsonTEBellmuntJPortaCSorafenib TARGET Clinical Trial GroupLong-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGETEur J Cancer201046132432244020656473
   PubMed Web of Science ®Google Scholar
• AdamsVRLeggasMSunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumorsClin Ther20072971338135317825686
   PubMed Web of Science ®Google Scholar
• ProcopioGBellmuntJDutcherJSorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysisBr J Cancer2013108231131823322192
   PubMed Web of Science ®Google Scholar
• KhakooAYKassiotisCMTannirNHeart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitorCancer2008112112500250818386829
   PubMed Web of Science ®Google Scholar
• MachielsJ PBletardNPirennePJacquetLBonbledFDuckLAcute cardiac failure after sunitinibAnn Oncol200819359759918272908
   PubMed Web of Science ®Google Scholar
• TelliMLWittelesRMFisherGASrinivasSCardiotoxicity associated with the cancer therapeutic agent sunitinib malateAnn Oncol20081991613161818436521
   PubMed Web of Science ®Google Scholar
• Di LorenzoGAutorinoRBruniGCardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysisAnn Oncol20092091535154219474115
   PubMed Web of Science ®Google Scholar
• SchmidingerMZielinskiCCVoglUMCardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinomaJ Clin Oncol200826325204521218838713
   PubMed Web of Science ®Google Scholar
• TolcherAWApplemanLJShapiroGIA phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancerCancer Chemother Pharmacol201167475176420521052
   PubMed Web of Science ®Google Scholar
• Al’AbadieMSKentGGGawkrodgerDJThe relationship between stress and the onset and exacerbation of psoriasis and other skin conditionsBr J Dermatol199413021992038123572
   PubMed Web of Science ®Google Scholar
• FortuneDGRichardsHLGriffithsCEPsychologic factors in psoriasis: consequences, mechanisms, and interventionsDermatol Clin200523468169416112445
   PubMed Web of Science ®Google Scholar
• CollamerANBattafaranoD FPsoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesisSemin Arthritis Rheum201040323324020580412
   PubMed Web of Science ®Google Scholar
• WierzbickaETouraniJMGuilletGImprovement of psoriasis and cutaneous side-effects during tyrosine kinase inhibitor therapy for renal metastatic adenocarcinoma. A role for epidermal growth factor receptor (EGFR) inhibitors in psoriasis? Br J Dermatol2006155121321416792781
   PubMed Web of Science ®Google Scholar
• MiyagawaSFujimotoHKoSHirotaSKitamuraYImprovement of psoriasis during imatinib therapy in a patient with a metastatic gastrointestinal stromal tumourBr J Dermatol2002147240640712174137
   PubMed Web of Science ®Google Scholar
• ZorzouMPStratigosAEfstathiouEBamiasAExacerbation of psoriasis after treatment with an EGFR tyrosine kinase inhibitorActa Derm Venereol200484430830915339078
   PubMed Web of Science ®Google Scholar
• O’ConnorJ PCaranoRAClampARQuantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imagingClin Cancer Res200915216674668219861458
   PubMed Web of Science ®Google Scholar
• ZenzREferlRKennerLPsoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteinsNature2005437705736937516163348
   PubMed Web of Science ®Google Scholar
• SchonthalerHBHuggenbergerRWculekSKDetmarMWagnerEFSystemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasisProc Natl Acad Sci U S A200910650212642126919995970
   PubMed Web of Science ®Google Scholar
• KunstfeldRHirakawaSHongYKInduction of cutaneous delayed-type hypersensitivity reactions in VEGF-A transgenic mice results in chronic skin inflammation associated with persistent lymphatic hyperplasiaBlood200410441048105715100155
   PubMed Web of Science ®Google Scholar
• WitteLHicklinDJZhuZMonoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategyCancer Metastasis Rev19981721551619770111
   PubMed Web of Science ®Google Scholar
• JungKLeeDLimHSDouble anti-angiogenic and anti-inflammatory protein Valpha targeting VEGF-A and TNF-alpha in retinopathy and psoriasisJ Biol Chem201128616144101441821345791
   PubMed Web of Science ®Google Scholar
• AgostaELazzeriSOrlandiPPharmacogenetics of anti-angiogenic and antineovascular therapies of age-related macular degenerationPharmacogenomics20121391037105322838951
   PubMed Web of Science ®Google Scholar
• CrawshawAAGriffithsCEMYoungHSInvestigational VEGF antagonists for psoriasisExpert Opin Invest Drugs2012213343
   PubMed Web of Science ®Google Scholar